Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The $16,000,000 would not come close to the amount of financing that would be needing to fund the phase 2b melanoma trial.
If this money is used for clinical trials, it would mot likely be for trials that have not yet started.
This doesn't show full depth but very telling. Dropped $0.0115 on a 1,000 share trade and then another $0.0139 on 21,000. Only a 1,000 shares separating $0.6265 and EOD $0.6011.
http://www.stockhouse.com/companies/level2/oncs/oncosec-medical-incorporated
Exactly, Level 2 says it all. Pure manipulation.
EOD manipulation - Time & Sales
If they are able to show great data for turning non responders into responders, it really makes me hope they license the technology. So many opportunities to treat solid tumors that it would be great to see all the big players take it and run. Even if it meant less overall profit for shareholders (not sure it would).
Sharebuilder showing a $0.0001 difference between the ask and bid price. Anyone see if that's where it was at close or is it always like that during AH? That's a tiny gap asking for buys if that's where it was during market hours.
I know I'm grasping for anything that may suggested a turn around.
While diversification is a fundamental investment strategy, I have decided to invest only in $ONCS. In fact I have 80% of my non retirement savings invested in $ONCS.
I'm not worried about losing everything my age. The older I get the less risk I'll take. If I sell ONCS for over $1 I'll never be in only one stock again but for now I believe it's the right strategy for me.
Thanks jbem777. That makes a lot of sense.
Knowing we have someone with $16+ million at stake makes holding shares easy.
Lasers,
New institutional investors have "lost" over $2,300,000(around 15%) since their investment. With our conversation over the weekend I feel like we're in agreement with the direction ONCS is going.
What are your thoughts to current PPS?
Anyone think the institution is still adding to their total before releasing quarterly filings?
I'm not concerned with PPS but find it interesting that someone with $16 million to invest wouldn't have MMs in place to assist in countering some of the MMs that may negatively effect the PPS. Or is sentiment just that bad towards ONCS where it can't be countered.
I refuse to believe someone invests $16,000,000 knowing only what retail investors know. Are they letting it ride knowing large catalysts are coming or are they accumulating more?
He's almost had to be in talks for the last 3-6 months with potential partners. I'd say their phone started ringing a little more frequently after interim data was released. What gives me confidence is that I believe his connections to INO have really benefited him to understand the importance of partnership terms. I believe he'll be careful to ensure the timing of the partnership is optimal.
I think we were all caught of guard with the private placement so I hate to play the timing game. With that said, how do we proceed with FDA discussions and phase 2b using PD-1 without having a partner? My guess is we have a partner in place with no finalized(or a just recently finalized) agreement. If that is the case I don't see a reason to hold off on announcement once terms are finalized.
My biggest question is who? Seems like it almost has to be Merck but I would think we would need 1 if not 2 other potentials to ensure terms are most favorable.
Simple answer - I don't know. Here's my guess/thoughts...
Institutional investors are not interested in taking a large stake right after a big run up. They use their deep pockets to leverage for or against a company and they can have extremely positive or negative effects on a stocks PPS.
I believe Punit wanted to see how ASCO effected the PPS. I think if we would have seen a run up prior to ASCO and hit the mid 90's after ASCO and created a strong base in the 90's that Punit would have held off on the offering. With the minimal effects of ASCO combined with the volatility of ONCS I think he felt it important to bring in an institution ASAP. I believe institutions have MM's that they work closely with to ensure the PPS is not manipulated against them.
I believe there are 3 important pieces to a young biotech: strong institutional investors, a large partner, and great technology/science behind it. Choosing an institution prior to a partner is much easier than after. A partner will join for the technology whereas an institution will join for the financial implications of the PPS and their investment. Now Oncosec has 2 of the 3 components and I believe will soon have the 3rd. It's frustrating to have 20%+ setback, but makes sense for the long term.
I also think the additional cash on hand puts Oncosec in a better position for partner negotiations but is a positive side effect and not a direct reason for the private offering.
While I understand where you are coming from, this is not possible. PPS is VERY important for any company that does not have revenue or a positive net income. Share offerings are a very large part of the process. If you need to raise $50 million it's much better to do it with a 25 million share offering than a 100 million share offering.
Shares outstanding is directly correlated to the PPS. The PPS needs to be monitored and addressed to ensure long term value! You're correct that market cap will take care of itself but for all shareholders(including Punit, institutions, retail investors, etc.) it's very important to keep the share's outstanding to a minimum.
Looks like we're there on the buy. Would love to see it hold and cross the 2M on volume.
Was posted here but "ASCO has Allotted ONCS More Time to Present"
This comes with being a featured presenter!
Yep, looks like Mensa was spot on! Easy to dislike the guy but he's got some good info.
Another Punit tweet:
@PunitDhillon: Nice to see @Oncosec P2 Melanoma data as the featured presenter on the #ASCO14 site: http://t.co/z3u7A4bupk #immunotherapy #ImmunoOncology
I've been thinking about this for awhile now with the low volume. Can you imagine a partnership PR Monday morning? All eyes would really be on $ONCS data Monday afternoon!
It'll get there either way but would make it very exciting for shareholders!
Read top pinned message on ASCO. Should be helpful.
Nothing new but I thought I'd share this post from brotherbear on Ymb:
Here is something to smile about all weekend
First, I would like to take a moment to say thank you to all Veterans and all citizens that have given their life to protect the lives of others. That is what Memorial Day is all about!
Regarding our ONCS. Remember that both MCC and T-cell have the potential for Orphan Designation and Approval, while Melanoma has the potential for Breakthrough Designation and Accelerated Approval. This means ALL our current Phase 2s are being set up for Phase 2Bs that will be designed to be pivotal trials and get ONCS to market without the need for Phase 3s. That is right, ALL the Phase 2s could receive approval upon the completion of Phase 2Bs. That is what AA and OA are all about. That is why Punit said they are planning the Phase 2B Melanoma trial to be a pivotal trial. That is why ONCS brought in Dr. Pierce and is working to partner with MERCK to use their MK-3475 which is currently under review for approval under BD.....AND....That is why the S-3 was filed so shares are available for the Partner (MERCK) to purchase and NOT for a public dilution.
All the pieces are there, all the signs have been given through the past presentations, believe what you want, but I am holding every share possible because ONCS is going to be doing some amazing things and very soon. I believe some of the low volume is because many are not convinced the S-3 will be for a private placement to a partner. That is unfortunate for them, because once the partner is announced they will be playing catch up and chasing that pps to buy in. Less
Great dialogue! Speculation is a crap shoot but fun to do! Unique opportunity we have!
Speaking of Shailender Bhatia... Here is an abstract for MCC.
http://abstracts.asco.org/144/AbstView_144_135135.html
Maybe totally unrelated to ONCS but seems to me that this could be very useful information when requesting orphan status.
Refresh...refresh...refresh.............
It's usually a minimum of a dollar for hedge funds but there is no set amounts for all. You'll find some buy for less and some won't touch a stock until its off the OTC.
TJ or anyone that knows the naked shorting data
It was my understanding that on Thursday there was 10 million+ shares in unfilled orders. How does that total compare to unfilled shares after today? Seems like they were pretty successful acquiring "cheap" shares today.
It is not illegal but it is tightly regulated on the major markets. I believe those regulations prevent market manipulation through naked shorting.
Wikipedia actually has a good explanation of naked shorting on different markets.
http://en.wikipedia.org/wiki/Naked_short_selling